Abstract: The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N2,N6-bis [N2,N6-bis(3,4,5-trihydroxybenzoyl)-L-lysyl]-N-(2-aminoethyl)-L-lys-inamide (TGDK) and fetuin.

Abstract: Cyclic peptides comprising, as a constituent chain or chains, one or two amino acid sequences selected from the groups consisting of the amino acid sequence Glu-Ala-Asp-Asp-Arg and the amino acid sequence Ser-Gln-Lys-Glu-Gly, and AIDS vaccines containing the cyclic peptide as an active ingredient. Preferably a cyclic dodecapeptide represented by the formula given below and an AIDS vaccine containing the cyclic dodecapeptide as an active ingredient. From the in vivo absorption and antibody formation viewpoint, active groups selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptide is preferably bound to substituent groups.

Abstract: Cyclic peptides which comprise, as a constituent chain or chains thereof, one or two amino acid sequences selected from the amino acid sequence Asn-Val-Ser-Glu-Ala-Asp-Asp-Arg-Tyr-Ile and the amino acid sequence Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr, and AIDS vaccines containing at least one of the cyclic peptides as an active ingredient. From the in vivo absorption and antibody expression viewpoint, a substituent group is preferably bound to at least one active group selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptides. The cyclic peptides can neutralize the second receptors which the HIV-1 virus utiliizes in the infection of humans therewith.

Abstract: An anti-HIV agent, an anti-HIV effect-potentiating agent and a prophylactic and remedial agent for AIDS each comprising, as an active ingredient, a vitamin B.sub.1 derivative such as thiamine disulfide, bisbentiamine, bisbutytiamine, bisibutiamine, alitiamine, fursultiamine or octotiamine, or the salt thereof.The agents according to the present invention are useful for prophylaxis of and treatment for AIDS because they have a very preferable nature that they inhibit the growth of HIV without killing cells against primarily infected cells, but exhibit both cell-killing effect and HIV-killing effect at the same time against persistent-production cells which have come to persistently produce HIV.